Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy.
Yasuhiro Tsutani, Yoshihiro Miyata, Haruhiko Nakayama...
https://pubmed.ncbi.nlm.nih.gov/24551879/Actively Recruiting
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2022-04-05
1120
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating whether segmentectomy is as effective as lobectomy for treating patients with early-stage non-small cell lung cancer that is 2 cm or smaller and located in the middle third of the lung. This study aims to determine if segmentectomy has similar long-term cancer control and survival outcomes compared to lobectomy, expanding on previous research focused on tumors in the outer third of the lung. Participants will be randomly assigned to receive either segmentectomy or lobectomy surgery. Both procedures aim to remove the tumor with clear margins R0 resection. The study monitors patients over several years to compare outcomes between the two surgical options. During the study, researchers will assess participants disease-free survival over five years as the main outcome. They will also track complications within 30 days after surgery, lung function during the first year, and overall survival at three and five years. The total follow-up period is up to five years after recruitment, with regular evaluations and lung function tests at specific intervals.
CONDITIONS
Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field
Z
Zhihua Li, M.D.
W
Weibing Wu, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 30 days
Participants undergo either segmentectomy or lobectomy surgery to remove lung tumors.
Approximately 1 surgery visit and follow-up visits during the first 30 days after surgery
Duration - Up to 5 years
Participants have their pulmonary function assessed and are monitored for disease-free survival and overall survival after surgery.
Visits at 3, 6, and 12 months for pulmonary function assessment, and additional visits for disease and survival monitoring up to 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yasuhiro Tsutani, Yoshihiro Miyata, Haruhiko Nakayama...
https://pubmed.ncbi.nlm.nih.gov/24551879/Wei-Bing Wu, Yang Xia, Xiang-Long Pan...
https://pubmed.ncbi.nlm.nih.gov/30390378/Nasser K Altorki, Xiaofei Wang, Dennis Wigle...
https://pubmed.ncbi.nlm.nih.gov/30442588/Kenji Suzuki, Hisashi Saji, Keiju Aokage...
https://pubmed.ncbi.nlm.nih.gov/31078312/Kenichi Nakamura, Hisashi Saji, Ryu Nakajima...
https://pubmed.ncbi.nlm.nih.gov/19933688/Weibing Wu, Zhicheng He, Jing Xu...
https://pubmed.ncbi.nlm.nih.gov/33524360/The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor